Анализ акций RENE.L
RE
Нет оценки
Количественный анализ Eyestock не покрывает акции ReNeuron Group PLC.
Рейтинг
Для оценки качества бизнеса компании мы собрали все финансовые данные из отчетов и представили их в виде одного числа - рейтинга компании. Значение рейтинга 100 является пороговым для определения актуальной инвестиционной идеи.
Низкий рейтинг
Капитализация млрд. $
0.039
Дивидендная доходность
—
Оборот
57.174 млрд
Сайт компании
http://www.reneuron.com/ReNeuron Group Plc engages in the development of novel cell based therapies that target significant areas of unmet medical need. The company is headquartered in Bridgend, Glamorgan and currently employs 36 full-time employees. The company went IPO on 2005-08-12. The Company’s stem cell derived Exosome Technology platform offers a delivery mechanism for a variety of payloads, such as small interfering Ribonucleic Acid (siRNA), messenger RNA (mRNA), proteins, small molecules and genes. The firm has two clinical-stage stem cell therapy candidate assets, a Phase 2a human retinal progenitor cell (hRPC) therapy candidate in retinitis pigmentosa and a Phase 2b immortalized neural progenitor cell therapy candidate (CTX) in stroke. The firm through its induced pluripotent stem cell (iPSC) platform has the ability to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.